GlassScriptPhysician profile
Jacob Stewart
NPI 1962909937
$1,495.65
in general payments reported to CMS, 2019-2025
15 companies · $651 in 2025
The $651 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.87 · 2023: $178 · 2024: $593 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,236.80 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $311.99 | 2023-2025 | |
| Janssen Biotech, INC. | $300.38 | 2024-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $243.36 | 2023-2025 | Skyrizi, Rinvoq |
| Novo Nordisk INC | $128.39 | 2025 | Ozempic, Rybelsus |
| Leo Pharma INC. | $104.72 | 2023-2025 | Adbry |
| Lilly USA, LLC | $84.77 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Allergan, INC. | $73.87 | 2021 | |
| Genzyme Corporation | $64.65 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $37.87 | 2024-2025 | Dupixent, Libtayo |
| Ucb, INC. | $33.66 | 2024 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $33.06 | 2025 | |
| Amgen INC. | $25.30 | 2024 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.45 | 2023 | Jublia |
| E.R. Squibb & Sons, L.L.C. | $18.21 | 2025 | Sotyktu |
| Biowound Solutions, INC. | $16.97 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.